Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Cetagliptin on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Cetagliptin is a once-daily tablet for type 2 diabetes, discovered and developed in China by CGeneTech (Suzhou), known in Chinese as 盛世泰科. Its Chinese name is 磷酸森格列汀片 (cetagliptin phosphate tablets) and its brand name is 盛捷维®; during development it was called 盛格列汀 and CGT-8012. It belongs to the DPP-4 inhibitor family of diabetes medicines, but has its own new chemical structure.
China's National Medical Products Administration (NMPA) approved it on 1 December 2024 as a Class 1 innovative drug (approval number 国药准字 H20240043), to improve blood sugar control in adults with type 2 diabetes:
It is a prescription endocrinology medicine and should be used under a diabetologist or endocrinologist.
After a meal, the gut releases hormones (GLP-1 and GIP) that tell the pancreas to release insulin. An enzyme called DPP-4 breaks these hormones down quickly. Cetagliptin blocks DPP-4, so the hormones stay active for longer and the body releases more insulin when blood sugar is high. Because it works with the body's own signals, it did not cause drug-related low blood sugar in its trial on its own.
Two phase 3 trials in China, both published in Diabetes, Obesity and Metabolism in 2023, compared it with placebo for 24 weeks, followed by 28 weeks of open treatment:
In both trials, people who started with a higher HbA1c (8.5% or more) saw bigger drops.
According to the Chinese prescribing information:
The trials also tested 100 mg once a day, which did not lower HbA1c more than 50 mg, and the approved dose is 50 mg. Your doctor will decide whether to continue your other diabetes medicines.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
In the trials: side effects were no more common with cetagliptin than with placebo, in either trial. There was no drug-related low blood sugar when it was used on its own, and adding it to metformin did not increase the overall risk of side effects. CGeneTech also reports that, over the following 28 weeks, side effects on 100 mg occurred at a rate similar to placebo.
Safety in pregnancy, breastfeeding and children has not been established in the published trials, so speak to your doctor first.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It does not appear in CDSCO's lists of new drugs approved in India, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. As it is a daily tablet for a long-term condition, we usually plan supply a few months at a time.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The tablets are stored as directed on the pack and travel in their sealed original packs under temperature-controlled shipping. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating clinic on a valid doctor's prescription.
Diabetes specialists in Delhi treat patients from across North India, and our New Delhi dispatch point keeps delivery quick.
Doctors in Mumbai can request the tablets for a named patient, with a few months of supply planned together.
Patients in Bangalore can have the medicine delivered home or to their clinic after the prescription is checked.
The treating diabetologist can send us the prescription and HbA1c report to start the import.
Endocrinologists in Hyderabad can arrange access for patients whose doctor wants to try this newer daily tablet.
For Kolkata and the eastern states, we time each delivery so there is no gap between packs.
Patients in Pune can use the same documented import route, with updates at every step.
Doctors across Gujarat can request supply for individual patients through the Named Patient Program.
Patients in Jaipur and the rest of Rajasthan can receive the tablets at home or at the clinic.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or treating doctor.
We deliver to patients and diabetes clinics across Uttar Pradesh.
Patients in Kochi and across Kerala can receive the medicine through the same legal route.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
